Michelson Diagnostics Ltd., the London-based manufacturer of optical coherence tomography (OCT) products, has been awarded a grant worth more than $41,500 from the UK government’s Technology Strategy Board (TSB). The funds are for a study into the feasibility of highly miniaturized OCT probes for cancer diagnoses. According to TSB data, 700 applications for funding were received, but just 69 were funded. CEO Jon Holmes said the project will help Michelson determine which technologies to use in the development of practical rigid and/or flexible OCT probes, for attachment to the proprietary “VivoSight” multibeam OCT platform. He added that, to develop the project, he is interested in receiving approaches from partners such as suppliers of miniature components, customers who can help specify the design, and commercial partners with an interest in applications for miniature OCT probes.